U.S. Markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
82.33-0.34 (-0.41%)
At close: 5:37PM CEST
People also watch
Full screen
Previous Close82.67
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range82.16 - 83.29
52 Week Range66.72 - 92.97
Avg. Volume2,413,297
Market Cap100.4B
PE Ratio (TTM)11.39
Earnings DateN/A
Dividend & Yield3.30 (3.47%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Barrons.com12 hours ago

    Eli Lilly: The Competition is Just Too Darn Intense!

    Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ...

  • Reuters2 days ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks5 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.